F-18-fluorodeoxyglucose positron-emission tomography (FDG-PET)-Radiomics of metastatic lymph nodes and primary tumor in non-small cell lung cancer (NSCLC) - A prospective externally validated study by Carvalho, Sara et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/189992
 
 
 
Please be advised that this information was generated on 2018-04-11 and may be subject to
change.
RESEARCH ARTICLE
18F-fluorodeoxyglucose positron-emission
tomography (FDG-PET)-Radiomics of
metastatic lymph nodes and primary tumor in
non-small cell lung cancer (NSCLC) – A
prospective externally validated study
Sara Carvalho1, Ralph T. H. Leijenaar1, Esther G. C. Troost1,2,3,4, Janna E. van Timmeren1,
Cary Oberije1, Wouter van Elmpt1, Lioe-Fee de Geus-Oei5,6,7, Johan Bussink8,
Philippe Lambin1*
1 Department of Radiation Oncology (MAASTRO), GROW–School for Oncology and Developmental
Biology, Maastricht University Medical Center (MUMC +), Maastricht, the Netherlands, 2 Institute of
Radiooncology—OncoRay, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany, 3 Department of
Radiotherapy and Radiation Oncology, Medical Faculty and University Hospital Carl Gustav Carus of
Technische Universita¨t Dresden, Dresden, Germany, 4 OncoRay, National Centre for Radiation Research in
Oncology, Medical Faculty and University Hospital Carl Gustav Carus of Technische Universita¨t Dresden,
Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany, 5 Department of Radiology and Nuclear
Medicine, Radboud UMC, Nijmegen, the Netherlands, 6 Department of Radiology, Leiden University Medical
Center, Leiden, the Netherlands, 7 Biomedical Photonic Imaging Group, MIRA Institute, University of Twente,
Enschede, the Netherlands, 8 Department of Radiation Oncology, Radboud University Medical Center,
Nijmegen, the Netherlands
* sarajbc@gmail.com
Abstract
Background
Lymph node stage prior to treatment is strongly related to disease progression and poor
prognosis in non-small cell lung cancer (NSCLC). However, few studies have investigated
metabolic imaging features derived from pre-radiotherapy 18F-fluorodeoxyglucose (FDG)
positron-emission tomography (PET) of metastatic hilar/mediastinal lymph nodes (LNs). We
hypothesized that these would provide complementary prognostic information to FDG-PET
descriptors to only the primary tumor (tumor).
Methods
Two independent cohorts of 262 and 50 node-positive NSCLC patients were used for model
development and validation. Image features (i.e. Radiomics) including shape and size, first
order statistics, texture, and intensity-volume histograms (IVH) (http://www.radiomics.io/)
were evaluated by univariable Cox regression on the development cohort. Prognostic
modeling was conducted with a 10-fold cross-validated least absolute shrinkage and
selection operator (LASSO), automatically selecting amongst FDG-PET-Radiomics
descriptors from (1) tumor, (2) LNs or (3) both structures. Performance was assessed with
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Results
Common SUV descriptors (maximum, peak, and mean) were significantly related to overall
survival when extracted from LNs, as were LN volume and tumor load (summed tumor and
LNs’ volumes), though this was not true for either SUV metrics or tumor’s volume. Feature
selection exclusively from imaging information based on FDG-PET-Radiomics, exhibited
performances of (1) 0.53 –external 0.54, when derived from the tumor, (2) 0.62 –external
0.56 from LNs, and (3) 0.62 –external 0.59 from both structures, including at least one fea-
ture from each sub-category, except IVH.
Conclusion
Combining imaging information based on FDG-PET-Radiomics features from tumors and
LNs is desirable to achieve a higher prognostic discriminative power for NSCLC.
Introduction
Non-small cell lung cancer (NSCLC) patients often present with hilar and/or mediastinal
lymph node involvement at diagnosis or during the course of disease. Lymph node stage prior
to treatment is strongly related to disease progression and worse prognosis [1]. Furthermore, it
affects treatment selection and target volume definition, for metastatic lymph nodes in patients
eligible for high-dose (chemo)radiotherapy [2].
In this study we hypothesized that the local selection of more aggressive cancer cells in the
metastatic hilar/mediastinal lymph nodes, being likely to determine prognosis, may provide an
additional and valuable source of information to the primary tumor for NSCLC patients. A
Radiomics-based approach comprises the extraction of a large set of imaging descriptors [3].
The underlying hypothesis is that biomarkers of imaging phenotypes deliver complementary
and clinically relevant information, which could be incorporated into individualized radiation
oncology approaches and shared decision-making tools [4–7]. To demonstrate this, we per-
formed a combined Positron Emission Tomography (PET) Radiomics analysis of metabolic
activity as measured with 18F–fluorodeoxyglucose (FDG) uptake in both primary tumor and
metastatic lymph nodes, and further validated these results in an independent cohort.
Patients and methods
Development cohort
Patient population. The prospective data collection was approved by the Institutional
Review Board of the Department of Radiotherapy of Maastricht University Medical Center
(MAASTRO clinic) (clinicaltrials.gov NCT00522639). Electronic medical charts of NSCLC
patients were reviewed. Patients undergoing surgery, Stereotactic Body Radiotherapy (SBRT)
or palliative treatment, or who had a previous malignancy within five years prior to diagnosis
were excluded from analysis. A total of 343 NSCLC patients (stage I-IIIB) referred to curative
treatment (between May 2006 and September 2012) were selected for the development cohort.
Out of these, 262 patients (76%) had metastatic lymph nodes. Patients received high-dose
FDG-PET-radiomics of tumor and lymph nodes in NSCLC
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radiotherapy (RT), planned on a dedicated FDG-PET-CT scan, combined with chemotherapy.
Clinical follow-up was performed according to national guidelines. All patients in the develop-
ment cohort provided informed written or verbal consent to data inclusion in clinical studies.
Image acquisition. Before scanning, patients fasted for at least 6 hours. Two different pro-
tocols were used: until December 2010, the total dose of FDG was calculated as (bodyweight x
4 + 20) MBq, and as from January 2011, the administered dose was (2.5 x bodyweight) MBq as
defined by the NEDPAS protocol [8]. FDG-PET-CT images were taken 60-minutes post injec-
tion. Data acquired until December 2006 were gathered on Siemens Biograph 16 CT-PET
scanner, and from that time onwards on a Siemens Truepoint 40 CT-PET (Siemens Healthcare
AG, Erlangen, Germany). An Ordered Subset Expectation Maximization 2D 4 iterations 8 sub-
sets (OSEM2D 4i8s) algorithm was used for image reconstruction using post-reconstruction
5mm Gaussian filtering, and voxel size of 4.0728 x 4.0728 x 3 (mm). Model-based methods
were applied for scatter correction. All PET scans were corrected for attenuation using the
mid-ventilation phase of the 4DCT or a 3DCT thorax in case the 4DCT was not of sufficient
image quality due to irregular breathing of the patient. All exams were corrected for random
events and decay.
Validation cohort
Patient population. The validation cohort included 215 stage I-IIIB NSCLC patients,
treated with primary radio(chemo)therapy between May 2006 and October 2012 at the
Department of Radiotherapy of Radboud UMC Nijmegen, following same inclusion and
exclusion criteria as for development cohort. In total 115 (53%) patients were node-positive, of
which 50 (23%) had an available treatment planning FDG-PET-CT. All patients in the valida-
tion cohort provided informed written or verbal consent to data inclusion in clinical studies.
Image acquisition. Before scanning, patients fasted for at least 6 hours. FDG-PET scans
were performed 60 minutes after intravenous injection of approximately 250 MBq FDG (Covi-
dien, Petten, the Netherlands) and 10 mg furosemide. PET scans were performed on Siemens
Biograph Duo (Siemens Medical Solutions USA, Inc.) using three-dimensional emissions of 4
minutes per bed position as described previously [9]. A low-dose CT scan for localization and
attenuation-correction purposes was acquired. Scanning parameters included 40 mAs (50
mAs for patient weight >100 kg and 60 mAs if>120 kg), 130 kV, 5-mm slice collimation,
0.8-second rotation time, and pitch of 1.5, reconstructed with 3-mm slices for smooth coronal
representation. An OSEM2D 4i16s algorithm was used for PET image reconstruction, with a
voxel size of 5.3 x 5.3 x 3.375 (mm). All PET scans were corrected for attenuation using CT
and simulation approaches. Model-based methods were applied for scatter correction. All
exams were corrected for random events and decay.
Regions of interest (ROI)
Images were imported into the research treatment planning system Xio/Focal (development
cohort) and Eclipse (validation cohort) using the DICOM protocol. The primary gross tumor
volume (tumor) and metastatic hilar/mediastinal lymph nodes (LN), identified as PET positive
and/or proven by endoscopic ultrasound bronchoscopy/esophagoscopy (EBUS/EUS), were
manually delineated by experienced radiation oncologists on the fused FDG-PET-CT images,
and used as the regions of interest for analysis [10–12]. A single structure representing all met-
astatic lymph nodes, regardless of their number, was derived for each patient (see online
appendix for further details).
FDG-PET-radiomics of tumor and lymph nodes in NSCLC
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Image analysis
In-house developed software was used to extract Radiomics descriptors from the FDG-PET
scans [13–16]. Imaging descriptors comprised first order statistics (n = 16), shape and size
(n = 13), intensity volume histograms (n = 45), and textural features describing the spatial dis-
tribution of voxel intensities (n = 44). Textural features were calculated from grey-level co-
occurrence (GLCM), grey-level run-length (GLRLM) and grey-level size-zone texture matrices
(GLSZM). To determine these matrices, images were first discretized with a bin width of 0.5
(Standardized Uptake Value or SUV), according to:
ID xð Þ ¼
IðxÞ
0; 5
 
  min
IðxÞ
0; 5
  !
þ 1
Where I is the original image, I(x) represents the SUV of voxel x, and ID is the resulting dis-
cretized image [15]. Texture matrices were then constructed by considering 26 connected vox-
els (i.e. voxels were considered to be neighbors in all 13 directions in three dimensions) at a
distance of 1 voxel. Features derived from GLCM and GLRLM were calculated by averaging
their value over all 13 directions. Forty-four textural features were extracted (22 GLCM, 11
GLRLM and 11 GLSZM). In total, 118 imaging features were calculated based on the
FDG-PET distribution within ROI, which mathematical formulations are detailed in the work
of Leijenaar et al. [14]. Image analysis was performed in Matlab R2012b (The Mathworks,
Natick, MA), based on an adapted version of Computational Environment for Radiotherapy
Research (CERR) [17].
Statistical analysis
Study parameters/endpoints. Primary endpoint of the study was overall survival (OS),
defined as the time from the start of radiotherapy until the last day of follow-up or death due
to any cause, and was available for all patients under analysis. A patient still alive at the end of
the study was regarded as right-censored.
Univariable analysis. A pre-feature selection was performed as detailed in the online
appendix. Imaging and clinical features were analyzed as continuous variables in a univariable
Cox regression. In addition, a correlation analysis was conducted for maximum, peak, and
mean SUV, and volume of tumor and LNs, and tumor load (sum of tumor and LN volumes).
Multivariable analysis. A prognostic model was fitted to the data with a 10-fold cross-val-
idated least absolute shrinkage and selection operator (LASSO), selecting amongst PET-Radio-
mics descriptors extracted from the tumor (model 1), LN (model 2) and the union of both
structures (model 3) [18]. LASSO selects variables correlated to the measured outcome by
shrinking down to zero coefficients weights for features non-related to outcome. Features
were entered in the model as continuous variables. Regression coefficients, hazard ratios (HR)
and confidence intervals (CI) were estimated using the whole development cohort. A diagram
illustrating this methodology is shown in Fig 1. Log-likelihood tests for non-nested models,
Akaike information criterion (AIC), were performed to compare the fit of the three derived
and independent models. AIC measures the relative quality of model fit to a given cohort, pro-
viding substantiation for model selection, i.e. the one with the lower AIC is the preferred
model [19]. Log-linearity assumption was verified for the selected features in the final models
by fitting a penalized smoothing spline. Cox proportional hazards assumption was graphically
examined with the Schoenfeld residuals.
Model performance. Model performance was assessed in the development and validation
cohorts by means of a concordance-index and corresponding 95% CI [20]. Concordance-
FDG-PET-radiomics of tumor and lymph nodes in NSCLC
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index or Harrell’s C-index, evaluates the fraction of patient pairs for which the predicted and
actual outcome are concordant, ranging from a random 0.5 to a perfect 1 [21].
All statistical analysis was conducted in R (version 2.15.2), using the libraries: survival, surv-
comp, glmnet, cvTols and rms [22]. The development cohort is publicly available at at www.
cancerdata.org and Dryad (doi:10.5061/dryad.752153b).
Results
Table 1 gives a complete overview of patients under analysis including treatment details.
Node-positive patients with available FDG-PET-CT scans were included in the analysis: 262
for development and 50 for validation phase. A univariable analysis was performed for each of
the clinical variables in the development cohort (Table 2). Results show that TNM staging was
not correlated to OS, while N stage was a prognostic factor at 0.1 level (p = 0.09) in the devel-
opment cohort, with higher stages being associated with a worse prognosis (hazard ratio (HR)
stage 2 = 1.44; HR stage 3 = 1.75). The number of LN stations was significantly associated with
a higher risk. Radiotherapy dose was also significantly associated with prognosis information.
None of the remaining analyzed metrics, including gender, age, histology and chemotherapy
showed a significant correlation to OS in our development cohort.
Results of univariable Cox regression of FDG-PET Radiomics features extracted from both
tumor and LNs are shown in the appendix (S2 File. Tables). Only short run emphasis from the
texture GLRLM group was significantly correlated to OS when extracted from the primary
tumor in the development set. On the other hand, metrics derived from LN showed a good
univariable correlation to outcome, with 13 of the 16 analyzed features being significantly
related to overall survival. Table 3 displays partial results of this analysis, for which a high Pear-
son correlation between metabolic features within each structure could be verified, but neither
a correlation could be found with own volume, nor with metabolic features of the other struc-
ture (Fig 2).
Three model approaches were derived and fitted to the data in the development cohort.
These are represented in Table 4, with corresponding hazard ratios and concordance-index.
Selected features were log-linear, except for LN volume, which had to be converted into a loga-
rithmic scale. The proportional hazards assumption was satisfied for all features. Graphical
assessment of these assumptions can be appreciated from Fig 3.
Fig 1. Diagram of the workflow followed in the multivariable model development phase. After a test-retest and inter-observer
study, 77 features remained for further analysis, based on a cut-off of 0.85 for the ICC analysis. Further identification of comparable
features extracted from the structure merging all metastatic lymph nodes (LNmerged) to the largest (LNvolume) or most active node
(LNmax), by means of an intraclass correlation (ICC) over 0.85 and ±10% limits of agreement (LoA) between measurements, was
performed (further details in S1 File. Feature pre selection). In summary, 77 features of the primary tumor and 16 from the metastatic
lymph nodes were entered in the model development phase.
https://doi.org/10.1371/journal.pone.0192859.g001
FDG-PET-radiomics of tumor and lymph nodes in NSCLC
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Discussion
Disease management of NSCLC is a primary concern, for which prognostic assessment is
essential to fulfil the potential of individualized and personalized treatment. Nowadays, a wide
range of information sources are available of which the non-invasive type play a fundamental
role in reducing the patients’ burden [4–6]. Among these, metabolic imaging has been increas-
ingly explored for prognosis assessment, based on SUV patterns of FDG of the primary tumor,
as an extension of its primary diagnostic function: detection of metastatic lymph nodes and
distant metastasis [23, 24].
NSCLC patients often present with lymph node involvement at diagnosis, which deeply
impacts prognosis and response to treatment [1, 2]. Apart from the number of metastatic
lymph node stations, lymph node size and corresponding metabolic activity may vary among
Table 1. Demographics and clinical information of development and validation cohorts.
Development dataset (n = 262) Validation dataset (n = 50)
Age
Mean ± SD 66±10 64±10
Range 33–86 44–83
Gender
Male 172 65.6% 31 62%
Female 90 34.4% 19 38%
Stage
II 10 3.8% - -
IIIa 107 40.8% 32 64%
IIIb 144 55% 18 36%
No information 1 0.4% 2 4%
N stage
1 28 10.7% 1 2%
2 151 57.6% 36 72%
3 80 30.5% 6 12%
No information 3 1.2% 7 14%
Number of metastatic LN stations
Mean ± SD 3.6 ± 2.4 2.1 ± 1.1
Range 1–12 1–6
Histology
Adenocarcinoma 60 22.9% 19 38%
Squamous cell carcinoma 73 27.9% 18 36%
NSCLC-otherwise specified (NOS) 123 46.9% 13 26%
No information 6 2.3% - -
Radiotherapy Dose
Mean ± SD 64.4 ± 7.5 61.8 ± 6.1
Range 45–99.75 45–70
Chemotherapy
Yes 227 86.6% 33 66%
No 25 9.6% - -
No information 10 3.8% 17 34%
 If no further information about stage was available in the EMD, TNM was reviewed and stage N0 and M1 patients were excluded from analysis
 Only 6 out of the 262 patients from the development dataset and 2 out of the 50 patients in the validation dataset received a dose under 50 Gy. Based on an individual
assessment of the medical records of each of these patients, we could find no evidence to justify removing these from the final analysis.
https://doi.org/10.1371/journal.pone.0192859.t001
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patients [25]. Diagnosis of metastatic hilar/mediastinal lymph nodes is commonly performed
through FDG-PET-CT and consecutive EBUS/EUS or mediastinoscopy [26–30]. Diffusion-
weighted magnetic resonance imaging (DWI) is also a solid alternative for lymph node detec-
tion, as proven by the work of Shen et. al [31]. In the work carried out, given the availability of
FDG-PET-CT scans for all patients under analysis as part of their protocol for radiotherapy
treatment, we proceeded the analysis with lymph nodes detected using this imaging modality.
Based on the rationale that disease progression and the ability to metastasize are closely related
to the presence of metastatic lymph nodes, we hypothesized that FDG-PET-based Radiomics
information of these nodes would provide additional prognostic information to the informa-
tion that is obtained from the primary tumor [23]. Radiomics has been proven to have prog-
nostic potential in predicting clinical outcomes or treatment monitoring in different cancer
types [13, 16, 32, 33] and can essentially be applied to different medical imaging modalities
and disease-related structures such as the primary tumor, metastatic lymph nodes or meta-
static lesions.
Common clinical metrics associated with disease prognosis, including TNM staging
(p = 0.92), could not be attributed statistical significance in the development cohort. Neverthe-
less, patients were staged in accordance to later editions of the classification system, that newer
classification as updated by the 8th edition may overcome [34]. On the other hand, higher
number of metastatic lymph nodes could be associated with a statistical significant higher risk
Table 2. Univariable Cox regression of clinical variables in development cohort.
Feature HR p-value HR 95% CI
Age 0.99 0.10 0.97–1.00
Gender
Male Reference
Female 0.85 0.30 0.63–1.15
Stage
II Reference
IIIa 1.05 0.92 0.48–2.28
IIIb 1.06 0.49–2.28
N stage
1 Reference
2 1.44 0.09 0.86–2.40
3 1.75 1.02–2.99
Number of metastatic LN stations
1 Reference
2 2.08 <0.01 1.30–3.30
3 1.65 0.98–2.99
4 1.95 1.28–2.98
Histology
Squamous cell carcinoma Reference
Adenocarcinoma 0.93 0.18 0.61–1.42
NSCLC-otherwise specified (NOS) 1.26 0.89–1.78
Radiotherapy Dose 0.98 0.03 0.96–0.99
Chemotherapy
No Reference
Yes 1.01 0.11 0.99–1.03
Hazard Ratios (HR) and corresponding p-values and 95% confidence intervals (CI)
https://doi.org/10.1371/journal.pone.0192859.t002
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(p<0.01), already anticipating the extra information these structures may provide, that we fur-
ther evaluated through imaging descriptors.
Given the broad range of imaging descriptors analyzed by a Radiomics approach, an initial
step in this analysis was to perform an exploratory univariable analysis of the most commonly
analyzed PET metrics when extracted from tumor and LNs, namely maximum, peak, and
mean SUV, volume and tumor load. None of the metabolic metrics extracted from tumor had
Table 3. Distribution of common PET descriptors (maximum, peak and mean) and volume of the primary tumor and LNs.
Structure Features Range
(Mean ± SD)
HR p-value HR 95% CI HR c-index 95% CI
c-index
Primary Tumor Maximum SUV 1.0–32.5 (10.7±5.7) 1.00 0.95 0.97–1.03 0.51 0.40–0.58
Peak SUV 0.8–29.5 (8.6±4.9) 1.00 0.92 0.97–1.03 0.51 0.40–0.58
Mean SUV 0.3–15.6 (4.4±2.3) 0.99 0.73 0.92–1.06 0.53 0.44–0.62
Volume 0.3–702.4 (79.5±104.6) 1.00 0.47 1.00–1.00 0.51 0.43–0.60
Metastatic
Lymph Nodes
Maximum SUV 1.2–39.8 (8.3±5.4) 1.05 <0.01 1.02–1.08 0.58 0.49–0.67
Peak SUV 1.0–32.1 (6.4±4.4) 1.06 <0.01 1.03–1.10 0.58 0.49–0.66
Mean SUV 0.5–14.8 (3.5±1.9) 1.14 <0.01 1.06–1.23 0.57 0.48–0.66
Volume 0.7–325.9 (35.3±42.9) 1.01 <0.01 1.00–1.01 0.60 0.51–0.68
Tumor Load 3.8–709.6 (114.8±111.3) 1.01 0.03 1.00–1.01 0.58 0.49–0.66
Univariable Cox regression of common FDG-PET descriptors extracted from primary tumor and metastatic lymph nodes of the development cohort: Hazard Ratios
(HR) and corresponding p-values and 95% confidence intervals (CI); univariable performance expressed by concordance-index (c-index) and associated 95% CI.
 Mean SUV is a generalization of the mean SUV distribution across all independent metastatic lymph nodes, as extracted from a structure merging all nodes. Total load
refers to the combined volume of the primary tumor and metastatic lymph nodes.
https://doi.org/10.1371/journal.pone.0192859.t003
Fig 2. Pearson correlation plot for metabolic descriptors and volume of primary tumor and metastatic lymph
nodes in the development dataset.
https://doi.org/10.1371/journal.pone.0192859.g002
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significant prognostic value, whereas the same ones extracted from LNs were related to OS
and yielded an univariable C-index of at least 0.57 (Table 3). No statistical significance could
be associated with tumor volume (p = 0.47), as opposed to LN volume (p<0.01; c-index 0.60,
95% CI = 0.51–0.68). Tumor load, sum of tumor and LNs volumes, also had prognostic value,
in line with previous studies [35]. Despite the strong correlation between metabolic features
within each structure, neither a correlation with own volume, nor with metabolic features of
the other structure could be found, contrary to previous evidence of correlation between maxi-
mum SUV of tumor and total LN volume [36]. One can already infer from this univariable
analysis the considerable prognostic value that the metabolic distribution within metastatic
lymph nodes has for node-positive NSCLC patients, which is further reinforced by remaining
features.
The main purpose of this study was to analyze imaging features extracted from the LNs and
compare it against the ones extracted from the primary tumor. In addition the non-univariable
statistical significance attributed to common clinical features (e.g. TNM staging), subsequent
modeling conducted solely on FDG-PET imaging features. Prior to development of the three
prognostic models, a pre-selection of the imaging features, comprising their stability and
robustness as discussed by Leijenaar et al. [14], and supported by Desseroit et al. [37], was con-
ducted and is discussed in the appendix section. Of the three derived independent fits, the
model with features from LNs alone or LNs in combination with primary tumor performed
best (c-index 0.62). The model included at least one feature from categories of shape and size,
first order statistics and texture descriptor, excluding features from the IVH group, despite
Table 4. Distribution of features included in the Cox regression model for FDG-PET-CT-based features extracted from pre-radiotherapy scans of NSCLC patients.
Tumor and nodes
separately
Tumor and nodes
combined
Model Features Range
(Mean ± SD)
Hazard
Ratios
p-
value
C-index
[95% CI]
Hazard
Ratios
p-
value
C-index
[95% CI]
Primary
Tumor
GLRLM–Short Run Emphasis
0.52–0.99 (0.89
±0.07)
0.13 0.04 0.53
[0.49–
0.58]
0.54
0.06 0.01 0.62
[0.58–
0.67]
0.59
Metastatic
Lymph Nodes
Shape–Volume 0.65–325.9 (35.3
±42.9)
0.93 0.47 0.62
[0.57–
0.66]
0.56
0.88 0.28
GLRLM–Grey Level Non-
uniformity
3.12–501.6 (68.5
±75.4)
1.00 0.02 1.00 0.02
GLRLM–Short Run High Grey
Level Emphasis
0.86–27.8 (5.76
±3.55)
1.03 0.83 - -
GLCM–Entropy 0.00–7.37 (3.82
±1.23)
- - 1.17 0.48
Shape–Surface/Volume 1.33–27.8 (5.76
±3.55)
0.90 0.41 0.94 0.67
Stats–Uniformity 0.02–0.89 (0.17
±0.12)
0.10 0.06 0.08 0.19
Analysis was conducted for primary tumor and metastatic lymph nodes separately, and for both structures in combination. Hazard Ratios (HR) and corresponding p-
values are reported. Performance of the model is expressed by internal and external concordance-index (C-index). Internal performance includes associated 95%
confidence-interval (CI) of the C-index.
Acronyms: GLCM–Grey Level Co-occurrence matrices; GLRLM–Grey Level Run-length matrices; Stats–first order statistics
 A logarithmic transformation was applied to LN volume
 External validation
https://doi.org/10.1371/journal.pone.0192859.t004
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Fig 3. Log-linear and proportional hazards assumptions verification. Graphically, log-linearity was verified by fitting a penalised smoothing spline on the univariable
effect of each variable included in models (left graph), while proportional hazards were analysed by plotting Schoenfeld residuals versus log (time) (right graph). These
included variables for LN, the (A) volume, (B) GLRLM grey level non-uniformity, (C) GLRLM short run high grey level emphasis, (D) GLCM entropy, (E) surface to
volume ratio, and (F) uniformity, and (G) GLRLM short run emphasis of tumour. All variables were log (linear), except LN volume (A left), for which a logarithmic
transformation was performed (A middle). All variables satisfied the proportional hazards assumption. Automatic feature selection for model 1 (based solely on primary
tumor imaging features) converged to a single metric of the GLRLM group—short run emphasis, with a C-index of 0.53 (95% confidence interval [CI] = 0.49–0.58) and
an external validation of 0.54. Model 2 (based on imaging features from LN) included total volume and the surface to volume ratio (shape), histogram uniformity (first
order statistics), grey level non-uniformity and short run high grey level emphasis (GLRLM of the textural group), reaching a C-index of 0.62 (95% CI = 0.57–0.66) with
an external validation of 0.56. Important to note that LN volume is an independent prognostic metric, with an univariable performance of 0.60 (95% CI = 0.51–0.68).
Finally, model 3 selected the same feature as model 1 and four features from the LN, replacing short run high grey level emphasis–GLRLM, by entropy–GLCM, and
reached a performance of 0.62 (95% CI = 0.58–0.67), and 0.59 in the external cohort. No metrics from the IVH sub-category were selected from any of the analyzed
structures for the derived models. Based on an AIC test, model 3 (1854.5) was shown to be a better fit than model 2 (1857.4), which itself was already a more precise fit
compared to model 1 (1876.4). In summary, the addition of nodal imaging information resulted in a better model fit, compared to a model based exclusively on features
derived from the primary tumor.
https://doi.org/10.1371/journal.pone.0192859.g003
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their proven univariable prognostic evidence in a previous study [38]. The intrinsic heteroge-
neity described by the FDG distribution within a primary tumor has proven its prognostic
power, not only for NSCLC, but also for other cancer types [39, 40]. Inclusion of such descrip-
tors in derived prognostic models, gathering heterogeneity insight into not only primary
tumor but also metastatic lymph nodes, resulted in a model with a better fit and more accurate
description of disease structures. Shape descriptors, including total LN volume, included in
the multivariable model, were shown to be an independent prognostic parameter. In a previ-
ous study, tumor load was revealed to be a prognostic factor, but not LN volume indepen-
dently, which we proved in this study [35]. Finally, and despite their univariate prognostic
value, particularly when assessed from LN, none of the most common SUV descriptors were
included in the final models. However, as Radiomics analysis includes a large number of fea-
tures, selection of the most promising ones is difficult. We attempted to overcome this diffi-
culty using an automatic feature selection routine (LASSO), to ensure an optimal exclusion of
redundant or highly correlated features from the final models derived, further complemented
with and external validation. Nonetheless, it cannot be completely excluded that other vari-
ables have similar or even greater prognostic value than the current ones, and therefore larger
imaging datasets are needed to validate and confirm our findings. Similarly, another limitation
of our study was the lack of additional patient data for the validation phase. A lower perfor-
mance is commonly observed when validating a model against new, independent, and external
cohorts, which is most frequently attributed to discrepancies between development and valida-
tion data [41]. A larger validation cohort would increase the robustness of the validation pro-
cedure. Nevertheless, we observed a benefit from combining imaging features from both
primary tumor and metastatic lymph nodes for node-positive NSCLC patients. In terms of
prognostics, this should not be disregarded, particularly when compared to the limited capac-
ity of humans to infer an accurate prognosis from same data [42]. In fact, the most commonly
accepted standard for disease prognosis assessment failed to provide a significant stratification
of risk patients (TNM stage).
A recent study with 139 NSCLC patients treated with at least 60Gy with a concurrent
(chemo)radiotherapy regimen showed the importance of measuring the post-treatment SUV
in the metastatic lymph nodes, as an increase in both the absolute value and percentage of
residual activity compared to the pre-treatment SUV were associated with worse local-regional
control [43]. In our study we looked only at the pre-treatment scan and could already discern
an association with OS of imaging features derived from the metastatic lymph nodes that
could not be assessed based on the primary tumor for node-positive patients. However, it is
hypothesized that the the variation of FDG-PET-Radiomics features between subsequent scans
at an early phase of treatment for both the primary tumor and the metastatic lymph nodes,
and their impact on survival for NSCLC patients as a complement to the positive findings
reported here. Also, a positive correlation between PET information derived from LNs and
overall relapse has been reported [44]. Our analysis focused primarily on overall survival, and
therefore we could not validate these findings. In the future we will be able to analyze this out-
come as we are currently improving our data collection routines, to further evaluate other out-
comes, actually limited to overall survival. Nevertheless, our findings emphasize the
importance of analyzing FDG-PET signal of metastatic lymph nodes prior to radiotherapy, to
further complement the information retrieved from the primary tumor.
Based on the positive and relevant findings we documented, we have plans to extend our
analysis in a similar manner to other disease sites, particularly head and neck cancer, for which
the involvement of the nodes is a well-known prognostic risk factor [45]. Likewise, we are also
aiming to analyze other PET tracers, particularly hypoxia markers (e.g. HX4) and compare the
results with FDG uptake [46, 47]. Further, it has been recently shown that combining
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Radiomics from both FDG-PET and low-dose CT can improve prognosis in NSCLC [48],
therefore, combining Radiomics from LNs extracted from the CT part of the FDG-PET-CT
would be a much desirable and natural step for future analysis with larger datasets. Seemingly,
other endpoints could obviously be analyzed following this Radiomics approach, namely
FDG-PET-Radiomics signal correlation to tumor marker. This rationale follows the correla-
tion demonstrated between maximum SUV and an increased expression of glucose transport-
ers 1 and p53 for adenocarcinoma NSCLC patients, but not squamous cell by the work of
Taylor et al. [49]. As pointed out, these studies need to take into consideration the effect of dif-
ferent tumor histology types, which correction was not performed in this work. Resistance of
p53-related chemotherapy has also been shown to be linked with maximum SUV by the work
of Duan et al. [50]. Correlation to therapy response was however not the subject of this study,
as the endpoint under analysis was overall survival due to any cause, but one can definitely
leave for future approaches the link between Radiomics descriptors and tumor markers related
to response to therapy.
In summary, common SUV descriptors derived from metastatic lymph nodes were associ-
ated with overall survival in a large cohort of NSCLC patients. Additionally, PET information
demonstrated to have higher prognostic value when extracted from metastatic lymph nodes in
comparison to the primary tumor alone, further complementing its information. The use of
3D information based on imaging is becoming a broader field with expected great gain for
patients’ outcomes assessment and treatment planning adaptations, following its application
to dissimilar structures as primary tumor, metastatic lymph nodes and possibly distant
metastasis.
Supporting information
S1 File. Feature pre selection. Methodology conducted for feature pre-selection for both pri-
mary tumor (tumor) and metastatic lymph nodes (LN), and corresponding results and inter-
pretation.
(DOCX)
S2 File. Tables. Univariable analysis of stable and robust Radiomics features from primary
tumor for development and validation datasets and that were common surrogates as extracted
from the merged and largest node as well as the merged and most active node, and therefore
entered as continuous variables in the multivariable model building.
(DOCX)
Acknowledgments
Authors acknowledge financial support from ERC advanced grant (ERC-ADG-2015, n˚
694812—Hypoximmuno) and the QuIC-ConCePT project, which is partly funded by EFPI A
companies and the Innovative Medicine Initiative Joint Undertaking (IMI JU) under Grant
Agreement No. 115151. This research is also supported by the Dutch technology Foundation
STW (grant n˚ 10696 DuCAT & n˚ P14-19 Radiomics STRaTegy), which is the applied science
division of NWO, and the Technology Programme of the Ministry of Economic Affairs.
Authors also acknowledge financial support from the EU 7th framework program (ART-
FORCE—n˚ 257144, REQUITE—n˚ 601826), SME Phase 2 (EU proposal 673780 –RAIL),
EUROSTARS (SeDI, CloudAtlas, DART), the European Program H2020-2015-17 (BD2De-
cide—PHC30-689715 and ImmunoSABR—n˚ 733008), Interreg V-A Euregio Meuse-Rhine
(“Euradiomics”), Kankeronderzoekfonds Limburg from the Health Foundation Limburg,
FDG-PET-radiomics of tumor and lymph nodes in NSCLC
PLOS ONE | https://doi.org/10.1371/journal.pone.0192859 March 1, 2018 12 / 16
Alpe d’HuZes-KWF (DESIGN), the Zuyderland-MAASTRO grant and the Dutch Cancer
Society. The authors report no conflicts of interest.
Author Contributions
Conceptualization: Sara Carvalho, Esther G. C. Troost, Philippe Lambin.
Data curation: Sara Carvalho, Ralph T. H. Leijenaar, Esther G. C. Troost, Lioe-Fee de Geus-
Oei.
Formal analysis: Sara Carvalho, Ralph T. H. Leijenaar, Esther G. C. Troost, Janna E. van Tim-
meren, Cary Oberije, Wouter van Elmpt.
Software: Ralph T. H. Leijenaar.
Validation: Sara Carvalho.
Writing – original draft: Sara Carvalho, Ralph T. H. Leijenaar, Esther G. C. Troost, Janna E.
van Timmeren, Cary Oberije, Wouter van Elmpt, Lioe-Fee de Geus-Oei, Johan Bussink,
Philippe Lambin.
References
1. Dehing-Oberije C, De Ruysscher D, van der Weide H, Hochstenbag M, Bootsma G, Geraedts W, et al.
Tumor volume combined with number of positive lymph node stations is a more important prognostic
factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiother-
apy. Int J Radiat Oncol Biol Phys. 2008; 70(4):1039–44. Epub 2007/09/25. https://doi.org/10.1016/j.
ijrobp.2007.07.2323 PMID: 17889446.
2. De Ruysscher D, Wanders S, van Haren E, Hochstenbag M, Geeraedts W, Utama I, et al. Selective
mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a
prospective clinical study. Int J Radiat Oncol Biol Phys. 2005; 62(4):988–94. Epub 2005/07/02. https://
doi.org/10.1016/j.ijrobp.2004.12.019 PMID: 15989999.
3. Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RG, Granton P, et al. Radiomics:
extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012;
48(4):441–6. https://doi.org/10.1016/j.ejca.2011.11.036 PMID: 22257792; PubMed Central PMCID:
PMCPMC4533986.
4. Lambin P, van Stiphout RG, Starmans MH, Rios-Velazquez E, Nalbantov G, Aerts HJ, et al. Predicting
outcomes in radiation oncology—multifactorial decision support systems. Nat Rev Clin Oncol. 2013; 10
(1):27–40. https://doi.org/10.1038/nrclinonc.2012.196 PMID: 23165123; PubMed Central PMCID:
PMCPMC4555846.
5. Lambin P, Petit SF, Aerts HJ, van Elmpt WJ, Oberije CJ, Starmans MH, et al. The ESTRO Breur Lec-
ture 2009. From population to voxel-based radiotherapy: exploiting intra-tumour and intra-organ hetero-
geneity for advanced treatment of non-small cell lung cancer. Radiother Oncol. 2010; 96(2):145–52.
Epub 2010/07/22. https://doi.org/10.1016/j.radonc.2010.07.001 PMID: 20647155.
6. Lambin P, Zindler J, Vanneste B, van de Voorde L, Jacobs M, Eekers D, et al. Modern clinical research:
How rapid learning health care and cohort multiple randomised clinical trials complement traditional evi-
dence based medicine. Acta Oncol. 2015; 54(9):1289–300. Epub 2015/09/24. https://doi.org/10.3109/
0284186X.2015.1062136 PMID: 26395528.
7. Lambin P, Leijenaar RTH, Deist TM, Peerlings J, de Jong EEC, van Timmeren J, et al. Radiomics: the
bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017; 14(12):749–62.
Epub 2017/10/05. https://doi.org/10.1038/nrclinonc.2017.141 PMID: 28975929.
8. Boellaard R, Oyen WJ, Hoekstra CJ, Hoekstra OS, Visser EP, Willemsen AT, et al. The Netherlands
protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur
J Nucl Med Mol Imaging. 2008; 35(12):2320–33. Epub 2008/08/16. https://doi.org/10.1007/s00259-
008-0874-2 PMID: 18704407.
9. Schuurbiers OC, Meijer TW, Kaanders JH, Looijen-Salamon MG, de Geus-Oei LF, van der Drift MA,
et al. Glucose metabolism in NSCLC is histology-specific and diverges the prognostic potential of
18FDG-PET for adenocarcinoma and squamous cell carcinoma. Journal of thoracic oncology: official
publication of the International Association for the Study of Lung Cancer. 2014; 9(10):1485–93. Epub
2014/08/30. https://doi.org/10.1097/jto.0000000000000286 PMID: 25170642.
FDG-PET-radiomics of tumor and lymph nodes in NSCLC
PLOS ONE | https://doi.org/10.1371/journal.pone.0192859 March 1, 2018 13 / 16
10. Nguyen NC, Kaushik A, Wolverson MK, Osman MM. Is there a common SUV threshold in oncological
FDG PET/CT, at least for some common indications? A retrospective study. Acta Oncol. 2011; 50
(5):670–7. Epub 2011/01/21. https://doi.org/10.3109/0284186X.2010.550933 PMID: 21247262.
11. Peeters ST, Dooms C, Van Baardwijk A, Dingemans AM, Martinussen H, Vansteenkiste J, et al. Selec-
tive mediastinal node irradiation in non-small cell lung cancer in the IMRT/VMAT era: How to use E(B)
US-NA information in addition to PET-CT for delineation? Radiother Oncol. 2016; 120(2):273–8. Epub
2016/06/14. https://doi.org/10.1016/j.radonc.2016.05.023 PMID: 27291644.
12. Serra Fortuny M, Gallego M, Berna L, Monton C, Vigil L, Masdeu MJ, et al. FDG-PET parameters pre-
dicting mediastinal malignancy in lung cancer. BMC Pulm Med. 2016; 16(1):177. Epub 2016/12/10.
https://doi.org/10.1186/s12890-016-0338-6 PMID: 27931198; PubMed Central PMCID:
PMCPMC5146847.
13. Parmar C, Rios Velazquez E, Leijenaar R, Jermoumi M, Carvalho S, Mak RH, et al. Robust Radiomics
feature quantification using semiautomatic volumetric segmentation. PLoS One. 2014; 9(7):e102107.
https://doi.org/10.1371/journal.pone.0102107 PMID: 25025374; PubMed Central PMCID:
PMCPMC4098900.
14. Leijenaar RT, Carvalho S, Velazquez ER, van Elmpt WJ, Parmar C, Hoekstra OS, et al. Stability of
FDG-PET Radiomics features: an integrated analysis of test-retest and inter-observer variability. Acta
Oncol. 2013; 52(7):1391–7. Epub 2013/09/21. https://doi.org/10.3109/0284186X.2013.812798 PMID:
24047337; PubMed Central PMCID: PMCPmc4533992.
15. Leijenaar RT, Nalbantov G, Carvalho S, van Elmpt WJ, Troost EG, Boellaard R, et al. The effect of SUV
discretization in quantitative FDG-PET Radiomics: the need for standardized methodology in tumor tex-
ture analysis. Sci Rep. 2015; 5:11075. https://doi.org/10.1038/srep11075 PMID: 26242464; PubMed
Central PMCID: PMCPMC4525145.
16. Coroller TP, Grossmann P, Hou Y, Rios Velazquez E, Leijenaar RT, Hermann G, et al. CT-based radio-
mic signature predicts distant metastasis in lung adenocarcinoma. Radiother Oncol. 2015; 114(3):345–
50. https://doi.org/10.1016/j.radonc.2015.02.015 PMID: 25746350; PubMed Central PMCID:
PMCPMC4400248.
17. Deasy JO, Blanco AI, Clark VH. CERR: a computational environment for radiotherapy research. Med
Phys. 2003; 30(5):979–85. Epub 2003/05/30. https://doi.org/10.1118/1.1568978 PMID: 12773007.
18. Tibshirani R. The lasso method for variable selection in the Cox model. Stat Med. 1997; 16(4):385–95.
Epub 1997/02/28. PMID: 9044528.
19. Burnham KP, Anderson DR. Multimodel Inference: Understanding AIC and BIC in Model Selection.
Sociological methods and research. 2004; 33:261–304.
20. Harrell FE Jr., Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluat-
ing assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996; 15(4):361–87.
Epub 1996/02/28. https://doi.org/10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.
CO;2-4 PMID: 8668867.
21. Royston P, Altman DG. External validation of a Cox prognostic model: principles and methods. BMC
Med Res Methodol. 2013; 13:33. Epub 2013/03/19. https://doi.org/10.1186/1471-2288-13-33 PMID:
23496923; PubMed Central PMCID: PMC3667097.
22. Team RC. R: A language and environment for statistical computing. R Foundation for Statistical Com-
puting. 2.15.2 ed2015.
23. Paesmans M, Garcia C, Wong CY, Patz EF Jr., Komaki R, Eschmann S, et al. Primary tumour stan-
dardised uptake value is prognostic in nonsmall cell lung cancer: a multivariate pooled analysis of indi-
vidual data. Eur Respir J. 2015; 46(6):1751–61. Epub 2015/09/26. https://doi.org/10.1183/13993003.
00099-2015 PMID: 26405289.
24. de Groot PM, Carter BW, Betancourt Cuellar SL, Erasmus JJ. Staging of Lung Cancer. Clin Chest Med.
36(2):179–96. https://doi.org/10.1016/j.ccm.2015.02.004 PMID: 26024599
25. Teran MD, Brock MV. Staging lymph node metastases from lung cancer in the mediastinum. J Thorac
Dis. 2014; 6(3):230–6. Epub 2014/03/14. https://doi.org/10.3978/j.issn.2072-1439.2013.12.18 PMID:
24624287; PubMed Central PMCID: PMCPMC3949187.
26. Hellwig D, Graeter TP, Ukena D, Groeschel A, Sybrecht GW, Schaefers HJ, et al. 18F-FDG PET for
mediastinal staging of lung cancer: which SUV threshold makes sense? Journal of nuclear medicine:
official publication, Society of Nuclear Medicine. 2007; 48(11):1761–6. Epub 2007/10/19. https://doi.
org/10.2967/jnumed.107.044362 PMID: 17942814.
27. Lee AY, Choi SJ, Jung KP, Park JS, Lee SM, Bae SK. Characteristics of Metastatic Mediastinal Lymph
Nodes of Non-Small Cell Lung Cancer on Preoperative F-18 FDG PET/CT. Nuclear medicine and
molecular imaging. 2014; 48(1):41–6. Epub 2014/06/06. https://doi.org/10.1007/s13139-013-0244-2
PMID: 24900137; PubMed Central PMCID: PMCPMC4035153.
FDG-PET-radiomics of tumor and lymph nodes in NSCLC
PLOS ONE | https://doi.org/10.1371/journal.pone.0192859 March 1, 2018 14 / 16
28. Mirsadraee S, Oswal D, Alizadeh Y, Caulo A, van Beek E Jr. The 7th lung cancer TNM classification
and staging system: Review of the changes and implications. World journal of radiology. 2012; 4
(4):128–34. Epub 2012/05/17. https://doi.org/10.4329/wjr.v4.i4.128 PMID: 22590666; PubMed Central
PMCID: PMCPMC3351680.
29. van Baardwijk A, Bosmans G, Boersma L, Buijsen J, Wanders S, Hochstenbag M, et al. PET-CT-based
auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver vari-
ability in the delineation of the primary tumor and involved nodal volumes. Int J Radiat Oncol Biol Phys.
2007; 68(3):771–8. Epub 2007/04/03. https://doi.org/10.1016/j.ijrobp.2006.12.067 PMID: 17398018.
30. Grootjans W, de Geus-Oei LF, Troost EG, Visser EP, Oyen WJ, Bussink J. PET in the management of
locally advanced and metastatic NSCLC. Nat Rev Clin Oncol. 2015; 12(7):395–407. Epub 2015/04/29.
https://doi.org/10.1038/nrclinonc.2015.75 PMID: 25917254.
31. Shen G, Lan Y, Zhang K, Ren P, Jia Z. Comparison of 18F-FDG PET/CT and DWI for detection of medi-
astinal nodal metastasis in non-small cell lung cancer: A meta-analysis. PLoS One. 2017; 12(3):
e0173104. Epub 2017/03/03. https://doi.org/10.1371/journal.pone.0173104 PMID: 28253364; PubMed
Central PMCID: PMCPMC5333854.
32. Rao SX, Lambregts DM, Schnerr RS, van Ommen W, van Nijnatten TJ, Martens MH, et al. Whole-liver
CT texture analysis in colorectal cancer: Does the presence of liver metastases affect the texture of the
remaining liver? United European gastroenterology journal. 2014; 2(6):530–8. Epub 2014/12/03.
https://doi.org/10.1177/2050640614552463 PMID: 25452849; PubMed Central PMCID:
PMCPmc4245301.
33. Zhang H, Graham CM, Elci O, Griswold ME, Zhang X, Khan MA, et al. Locally advanced squamous cell
carcinoma of the head and neck: CT texture and histogram analysis allow independent prediction of
overall survival in patients treated with induction chemotherapy. Radiology. 2013; 269(3):801–9. Epub
2013/08/06. https://doi.org/10.1148/radiol.13130110 PMID: 23912620.
34. Giron J, Lacout A, Marcy PY. Dealing with Lung Cancer TNM Classification. Journal of thoracic oncol-
ogy: official publication of the International Association for the Study of Lung Cancer. 2016; 11(6):e77–
8. Epub 2016/05/24. https://doi.org/10.1016/j.jtho.2016.01.026 PMID: 27211581.
35. Dehing-Oberije C, Yu S, De Ruysscher D, Meersschout S, Van Beek K, Lievens Y, et al. Development
and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients
treated with chemoradiotherapy. International journal of radiation oncology, biology, physics. 2009; 74
(2):355–62. Epub 2008/12/20. https://doi.org/10.1016/j.ijrobp.2008.08.052 PMID: 19095367.
36. Wang Y, Ma S, Dong M, Yao Y, Liu K, Zhou J. Evaluation of the factors affecting the maximum stan-
dardized uptake value of metastatic lymph nodes in different histological types of non-small cell lung
cancer on PET-CT. BMC pulmonary medicine. 2015; 15:20. Epub 2015/04/17. https://doi.org/10.1186/
s12890-015-0014-2 PMID: 25880540; PubMed Central PMCID: PMCPMC4372315.
37. Desseroit MC, Tixier F, Weber WA, Siegel BA, Cheze Le Rest C, Visvikis D, et al. Reliability of PET/CT
Shape and Heterogeneity Features in Functional and Morphologic Components of Non-Small Cell Lung
Cancer Tumors: A Repeatability Analysis in a Prospective Multicenter Cohort. J Nucl Med. 2017; 58
(3):406–11. Epub 2016/10/22. https://doi.org/10.2967/jnumed.116.180919 PMID: 27765856; PubMed
Central PMCID: PMCPMC5331937.
38. Carvalho S, Leijenaar RT, Velazquez ER, Oberije C, Parmar C, van Elmpt W, et al. Prognostic value of
metabolic metrics extracted from baseline positron emission tomography images in non-small cell lung
cancer. Acta Oncol. 2013; 52(7):1398–404. Epub 2013/09/21. https://doi.org/10.3109/0284186X.2013.
812795 PMID: 24047338; PubMed Central PMCID: PMCPMC4464799.
39. Cook GJ, Yip C, Siddique M, Goh V, Chicklore S, Roy A, et al. Are pretreatment 18F-FDG PET tumor
textural features in non-small cell lung cancer associated with response and survival after chemora-
diotherapy? J Nucl Med. 2013; 54(1):19–26. Epub 2012/12/04. https://doi.org/10.2967/jnumed.112.
107375 PMID: 23204495.
40. Hatt M, Majdoub M, Vallieres M, Tixier F, Le Rest CC, Groheux D, et al. 18F-FDG PET uptake charac-
terization through texture analysis: investigating the complementary nature of heterogeneity and func-
tional tumor volume in a multi-cancer site patient cohort. Journal of nuclear medicine: official
publication, Society of Nuclear Medicine. 2015; 56(1):38–44. Epub 2014/12/17. https://doi.org/10.2967/
jnumed.114.144055 PMID: 25500829.
41. Toll DB, Janssen KJ, Vergouwe Y, Moons KG. Validation, updating and impact of clinical prediction
rules: a review. J Clin Epidemiol. 2008; 61(11):1085–94. Epub 2009/02/12. https://doi.org/10.1016/j.
jclinepi.2008.04.008 PMID: 19208371.
42. Oberije C, Nalbantov G, Dekker A, Boersma L, Borger J, Reymen B, et al. A prospective study compar-
ing the predictions of doctors versus models for treatment outcome of lung cancer patients: a step
toward individualized care and shared decision making. Radiother Oncol. 2014; 112(1):37–43. Epub
2014/05/23. https://doi.org/10.1016/j.radonc.2014.04.012 PMID: 24846083.
FDG-PET-radiomics of tumor and lymph nodes in NSCLC
PLOS ONE | https://doi.org/10.1371/journal.pone.0192859 March 1, 2018 15 / 16
43. Markovina S<, Duan F, Snyder BS, Siegel BA, Machtay M, Bradley JD. Regional Lymph Node Uptake
of [(18)F]Fluorodeoxyglucose After Definitive Chemoradiation Therapy Predicts Local-Regional Failure
of Locally Advanced Non-Small Cell Lung Cancer: Results of ACRIN 6668/RTOG 0235. (1879-355X
(Electronic)).
44. Li H, Becker N, Raman S, Chan TC, Bissonnette JP. The value of nodal information in predicting lung
cancer relapse using 4DPET/4DCT. Medical physics. 2015; 42(8):4727–33. Epub 2015/08/04. https://
doi.org/10.1118/1.4926755 PMID: 26233200.
45. Prabhu RS, Hanasoge S, Magliocca KR, Hall WA, Chen SA, Higgins KA, et al. Lymph node ratio influ-
ence on risk of head and neck cancer locoregional recurrence after initial surgical resection: implications
for adjuvant therapy. Head & neck. 2015; 37(6):777–82. Epub 2014/03/07. https://doi.org/10.1002/hed.
23662 PMID: 24596123.
46. Zegers CM, van Elmpt W, Reymen B, Even AJ, Troost EG, Ollers MC, et al. In vivo quantification of hyp-
oxic and metabolic status of NSCLC tumors using [18F]HX4 and [18F]FDG-PET/CT imaging. Clin Can-
cer Res. 2014; 20(24):6389–97. Epub 2014/10/16. https://doi.org/10.1158/1078-0432.CCR-14-1524
PMID: 25316821.
47. Pettersen EO, Ebbesen P, Gieling RG, Williams KJ, Dubois L, Lambin P, et al. Targeting tumour hyp-
oxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the
METOXIA consortium. Journal of enzyme inhibition and medicinal chemistry. 2015; 30(5):689–721.
Epub 2014/10/28. https://doi.org/10.3109/14756366.2014.966704 PMID: 25347767.
48. Desseroit MC, Visvikis D, Tixier F, Majdoub M, Perdrisot R, Guillevin R, et al. Development of a nomo-
gram combining clinical staging with (18)F-FDG PET/CT image features in non-small-cell lung cancer
stage I-III. Eur J Nucl Med Mol Imaging. 2016; 43(8):1477–85. Epub 2016/02/21. https://doi.org/10.
1007/s00259-016-3325-5 PMID: 26896298.
49. Taylor MD, Smith PW, Brix WK, Wick MR, Theodosakis N, Swenson BR, et al. Fluorodeoxyglucose
positron emission tomography and tumor marker expression in non-small cell lung cancer. J Thorac
Cardiovasc Surg. 2009; 137(1):43–8. Epub 2009/01/22. https://doi.org/10.1016/j.jtcvs.2008.10.014
PMID: 19154901; PubMed Central PMCID: PMCPMC3632077.
50. Duan XY, Wang W, Wang JS, Shang J, Gao JG, Guo YM. Fluorodeoxyglucose positron emission
tomography and chemotherapy-related tumor marker expression in non-small cell lung cancer. BMC
Cancer. 2013; 13:546. Epub 2013/11/19. https://doi.org/10.1186/1471-2407-13-546 PMID: 24237755;
PubMed Central PMCID: PMCPMC3835621.
FDG-PET-radiomics of tumor and lymph nodes in NSCLC
PLOS ONE | https://doi.org/10.1371/journal.pone.0192859 March 1, 2018 16 / 16
